Back to Home

Healthcare Affordability Access

Expert articles and analysis related to healthcare affordability access.

195 articlesLast 30 Days

AI Summary — Last 30 Days

CMS under the Trump administration is tightening federal control over affordability levers in public programs: proposed limits on Medicaid state-directed payments would materially reduce supplemental funding flows to hospitals and safety-net systems, while OBBBA-related Medicaid/CHIP changes raise near-term coverage and access risk for VBC organizations managing low-income populations. At the same time, Medicare Advantage remains a major pressure point for providers and patients, with 2026 plan design showing continued reliance on prior authorization, supplemental benefits, rebates, and out-of-pocket structures that can shift utilization and care-management burden onto delivery systems (KFF on MA in 2026). CMS is also using targeted affordability and program-integrity tools—such as the proposed $50 monthly access pathway for certain GLP-1s and a national moratorium on new Medicare hospice and home health enrollments—signaling that ACOs, MA plans, and risk-bearing providers should expect tighter scrutiny of high-growth spend categories, network adequacy, and downstream post-acute capacity (Medicaid payment crackdown).

Related Articles

98ALN

Medicare Drug Price Negotiation is here to stay

At least, it won’t be overturned by the US Supreme Court. Endpoints reports: The Supreme Court says it won’t wade into the pharma industry’s yearslong legal battle over Medicare drug price negotiation...

Healthcare EconomistMay 19, 2026
98ALN

SCOTUS rejects Medicare drug price negotiation appeals by drugmakers

SCOTUS rejects Medicare drug price negotiation appeals by drugmakers  Modern Healthcare News

Modern HealthcareMay 18, 2026
98ALN

Supreme Court declines to hear drugmakers' challenge to price negotiations

The Supreme Court this morning declined to hear an appeal from six drug manufacturers that wanted the court to reject the Medicare Drug Price Negotiation Program.The court refused to hear separate app...

Healthcare FinanceMay 18, 2026
95ALN

STAT+: Maryland state affordability board places a price cap on Ozempic

Nine states have been pursuing the idea of prescription drug affordability boards. Maryland's board just set limits on the price of Ozempic.

STAT NewsMay 18, 2026
95ALN

Supreme Court declines to hear drugmakers' challenge to price negotiations

Supreme Court declines to hear drugmakers' challenge to price negotiations  Healthcare Finance News

Healthcare Finance NewsMay 18, 2026
95ALN

STAT+: Supreme Court rejects challenge to Medicare drug price negotiation

The rejection may make the pharma firms remaining lawsuits more difficult.

STAT NewsMay 18, 2026
95ALN

The Supreme Court won't take up drugmakers' IRA cases

The Supreme Court says it won’t wade into the pharma industry’s yearslong legal battle over Medicare drug price negotiations. The justices declined to review multiple cases brought by AstraZeneca, J...

Endpoints NewsMay 18, 2026
95ALN

Drugmaker Patent Abuse Is Blocking Competition and Keeping Prices High

Drugmaker Patent Abuse Is Blocking Competition and Keeping Prices High  AHIP

AHIPMay 15, 2026
95ALN

STAT+: Top U.S. officials pressured Germany to pay more for prescription drugs

It's a key piece of Trump's effort to secure lower drug prices for U.S. patients.

STAT NewsMay 15, 2026
95ALN

Recent legislation has changed Ghost Networks from headline risk to a big, real liability. Here is what to do about it. - beckerspayer.com

Recent legislation has changed Ghost Networks from headline risk to a big, real liability. Here is what to do about it.  beckerspayer.com

Becker's Payer IssuesMay 13, 2026